Brown Rudnick represented Edwards Lifesciences Corp. (NYSE: EW) in connection with Edwards' structured investment in Harpoon Medical, Inc., a privately held medical technology company that is pioneering a beating-heart, transcatheter therapy for minimally invasive surgical repair of a degenerative mitral valve. The transaction included an upfront investment and an exclusive option to acquire Harpoon. The Brown Rudnick team representing Edwards was led by partners Rob Funsten and Katy Gardner and included associates Steve Cheng, Mary AmbacherJonathan Fitzsimons and Esther Lee. Support for the transaction was provided by partner Vince Guglielmotti and associate James Maynor (tax) and partners Rob Tosti (intellectual property) and Adam Cantor (employee benefits).

To learn more about this deal, please read the following press release:

https://finance.yahoo.com/news/edwards-lifesciences-outlines-growth-strategy-141500910.html